BCTG Avocats acts for a diverse client list which notably includes Teva Santé and Servier. Hugues Villey-Desmeserets regularly advises clients on commercial policy issues, in addition to competition and regulatory matters, areas in which François Dauba is also an expert. Gaëlle Bloret-Pucci has longstanding experience in IP litigation, often appearing before the Paris Commercial Court and Civil Court. Séverin Kullmann leads the firm’s M&A and private equity group, and assists clients with joint ventures and reorganisations.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘BCTG adapts its services to our specific needs, and offers tailored legal solutions, especially in the highly regulated sector of pharmaceuticals.’

  • ‘The team around Hugues Villey-Desmeserets is highly skilled.’
  • ‘We have been working with Hugues Villey-Desmeserets for years. Hugues is known for his practical approach and in-depth understanding of commercial challenges, which makes him a sought-after advisor for clients facing regulatory scrutiny or complex business transactions. His ability to combine legal strategy with an understanding of commercial imperatives is one of his key strengths, especially in dealing with pharmaceutical regulations and industry-specific legal matters.’

  • ‘I work regularly with Séverin Kullmann and I am very satisfied with our interactions. He is competent, available and full of suggestions.’

  • ‘Very pragmatic approach to cases.’

  • ‘François Dauba is an excellent partner in competition law.’

Key clients

  • Teva Santé
  • Stada
  • Kenvue
  • GenoSafe
  • NHCO Nutrition
  • Servier
  • Seqens
  • Iktos
  • EG427
  • Mailstone
  • Pharma Life Cycle Assessment

Work highlights

  • Assisting the PHARMA LCA CONSORTIUM which involves 18 global pharmaceutical companies (AstraZeneca, GSK, Johnson & Johnson, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda, etc.) in regular meetings to create product category rules for pharmaceutical products, allowing consistent assessments to deliver more environmentally sustainable pharmaceutical products.
  • Advised IKTOS, a French company specialised in the development of artificial intelligence solutions applied to the discovery of new treatments, in the context of the negotiation of a major contract with Elsevier for the creation of an AI platform for synthetic chemistry dedicated to drug discovery.

Practice head

The lawyer(s) leading their teams.

Hugues Villey-Desmeserets, François Dauba, Gaëlle Bloret-Pucci, Séverin Kullmann